<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Congenital hemangiomas: Rapidly involuting congenital hemangioma (RICH), noninvoluting congenital hemangioma (NICH), and partially involuting congenital hemangioma (PICH)</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Congenital hemangiomas: Rapidly involuting congenital hemangioma (RICH), noninvoluting congenital hemangioma (NICH), and partially involuting congenital hemangioma (PICH)</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Congenital hemangiomas: Rapidly involuting congenital hemangioma (RICH), noninvoluting congenital hemangioma (NICH), and partially involuting congenital hemangioma (PICH)</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Ilona J Frieden, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Denise M Adams, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Moise L Levy, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Rosamaria Corona, MD, DSc</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jun 30, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H13843064"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Congenital hemangiomas (CHs) are rare, benign vascular tumors that are present and fully grown at birth. They present as bossed plaques or exophytic masses located on the head, neck, or limbs  (<a class="graphic graphic_picture graphicRef88800 graphicRef88907" href="/d/graphic/88800.html" rel="external">picture 1A-B</a>). Based on their natural history, three major clinical subtypes of CH have been recognized: rapidly involuting congenital hemangioma (RICH); noninvoluting congenital hemangioma (NICH); and partially involuting congenital hemangioma (PICH), which shows overlapping features and clinical behavior of RICH and NICH [<a href="#rid1">1-3</a>].</p><p>CH will be discussed in this topic. Infantile hemangiomas, other vascular tumors of childhood, and capillary malformations are discussed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/5794.html" rel="external">"Infantile hemangiomas: Epidemiology, pathogenesis, clinical features, and complications"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/5793.html" rel="external">"Infantile hemangiomas: Evaluation and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/5792.html" rel="external">"Infantile hemangiomas: Management"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/86314.html" rel="external">"Tufted angioma, kaposiform hemangioendothelioma (KHE), and Kasabach-Merritt phenomenon (KMP)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/13736.html" rel="external">"Pyogenic granuloma (lobular capillary hemangioma)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/13726.html" rel="external">"Capillary malformations (port wine birthmarks) and associated syndromes"</a>.)</p><p></p><p class="headingAnchor" id="H13843071"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>The precise incidence of congenital hemangioma (CH) is unknown. In a prospective study, RICH occurred in 2 of 594 newborns (0.3 percent) [<a href="#rid4">4</a>]. In a retrospective review of 6459 children with vascular anomalies seen in a vascular anomalies center, CHs were diagnosed in 14 percent, infantile hemangiomas were diagnosed in 43 percent, and capillary malformations were diagnosed in 30 percent [<a href="#rid5">5</a>]. There are no known risk factors for CH. In contrast with infantile hemangioma, there is no association between CH and premature birth or multiple gestation [<a href="#rid6">6</a>].</p><p class="headingAnchor" id="H13843078"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>There is increasing evidence that most, if not all, congenital hemangiomas (CHs), whether rapidly involuting, noninvoluting, or partially involuting, are due to somatic activating mutations in <em>GNAQ</em> and its paralog <em>GNA11</em> [<a href="#rid7">7,8</a>]. This suggests that RICH, NICH, and PICH represent a disease spectrum rather than separate entities.</p><p>Pathogenic variants that alter glutamine at amino acid 209 (Gln209) in <em>GNAQ</em> or <em>GNA11</em> were found in all tested frozen-tissue samples from eight CHs collected during a clinically indicated procedure at frequencies ranging from 3 to 33 percent [<a href="#rid7">7</a>]. The same variants were found in three out of seven paraffin-embedded samples. The authors noted that since the same variants are found in both NICH and RICH, other factors must account for the differing clinical presentations and postnatal behaviors. Mutations in <em>GNA11/14</em> have been shown to constitutively activate mitogen-activated protein kinase (MAPK) signaling pathway [<a href="#rid9">9</a>].</p><p>Variants in <em>GNAQ</em> and <em>GNA11</em> are a common cause of port wine stains, but they are typically found in other alleles, such as <em>R183Q</em>. In one case report, an infant with a very large CH, as well as innumerable small vascular tumors, was found to have the same somatic variant in <em>GNA11</em> in both the large tumor and in two of the smaller tumors [<a href="#rid8">8</a>]. Two other types of hemangiomas have also been described as being due to Gln209 <em>GNAQ</em> variants: congenital hepatic hemangiomas [<a href="#rid7">7</a>] and anastomosing hemangiomas, a type of vascular tumor with adult onset that mostly occurs in the genitourinary tract and paravertebral soft tissues [<a href="#rid10">10</a>].</p><p>These genomic findings, together with immunohistochemical differences between CHs and infantile hemangiomas as well as differing biomarker expression, confirm that they are distinct entities rather than variants of the same vascular tumor [<a href="#rid11">11-13</a>]. At the same time, they link together RICH, NICH, and PICH as related entities, but the reasons they differ in clinical behavior are not well understood.</p><p class="headingAnchor" id="H13843085"><span class="h1">CLINICAL PRESENTATION</span></p><p class="headingAnchor" id="H1304428927"><span class="h2">Clinical subtypes</span><span class="headingEndMark"> — </span>Congenital hemangiomas (CHs) are present and fully grown at birth. They usually present as solitary, plaque-like or exophytic lesions varying from a few centimeters to &gt;10 cm in size  (<a class="graphic graphic_picture graphicRef88800 graphicRef88803 graphicRef88907 graphicRef88908" href="/d/graphic/88800.html" rel="external">picture 1A-D</a>).</p><p>Based on their natural history, three major clinical subtypes of CH have been recognized [<a href="#rid1">1-3</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Rapidly involuting congenital hemangioma (RICH)</p><p class="bulletIndent1"><span class="glyph">●</span>Noninvoluting congenital hemangioma (NICH)</p><p class="bulletIndent1"><span class="glyph">●</span>Partially involuting congenital hemangioma (PICH)</p><p></p><p>In most cases, RICH start rapidly regressing in the few weeks after birth and involute completely or nearly completely by the age of 14 months. NICH do not involute but typically grow in proportion with somatic growth [<a href="#rid14">14</a>]. PICH show clinical and behavioral features of both RICH and NICH; they undergo a phase of rapid involution and then stabilize without regressing completely [<a href="#rid1">1</a>]. Several reports have added another dimension to the natural history of CHs: those that continue to expand and progress over time [<a href="#rid15">15-19</a>].</p><p class="headingAnchor" id="H13843094"><span class="h2">Rapidly involuting congenital hemangiomas</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features</strong> – RICH are most often located in the head and neck region  (<a class="graphic graphic_picture graphicRef88800" href="/d/graphic/88800.html" rel="external">picture 1A</a>) or lower extremities [<a href="#rid2">2,20,21</a>]. They vary in size from a few centimeters to &gt;10 cm and are nearly always solitary, although rare examples of multifocal lesions have been reported [<a href="#rid22">22,23</a>]. Several morphologic variants have been described, including:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A raised, violaceous soft tissue mass with prominent peripheral veins  (<a class="graphic graphic_picture graphicRef88800" href="/d/graphic/88800.html" rel="external">picture 1A</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A soft tissue mass with overlying, prominent, coarse telangiectasias admixed with a blanched skin, including a halo of blanched skin at the periphery of the tumor  (<a class="graphic graphic_picture graphicRef88803" href="/d/graphic/88803.html" rel="external">picture 1C</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A pink to violaceous tumor with a deeper dermal or subcutaneous infiltration</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Exophytic vascular tumor with central ulceration [<a href="#rid24">24</a>]</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A vascular tumor with overlying pustules [<a href="#rid25">25</a>]</p><p></p><p class="bulletIndent1">On palpation, lesions are typically warmer than the surrounding skin. Occasionally, a bruit can be heard or a thrill can be felt.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical course and sequelae</strong> – The involution of RICH typically starts a few days to a few weeks after birth and, in most cases, is complete in 6 to 14 months. In rare instances, involution may occur in utero<em> </em>[<a href="#rid26">26</a>]. Involution leaves areas of skin redundancy with dermal or subcutaneous atrophy, textural and color changes, and persistent telangiectasias or scattered veins  (<a class="graphic graphic_picture graphicRef88807" href="/d/graphic/88807.html" rel="external">picture 2</a>). Other local sequelae include permanent alopecia, superficial scarring, and milia formation [<a href="#rid2">2,27,28</a>].</p><p></p><p class="bulletIndent1">In a small proportion of patients with RICH, involution is incomplete and leaves a vascular plaque with coarse telangiectasias on the surface and a peripheral, bluish-white border indistinguishable from NICH [<a href="#rid3">3</a>]. (See <a class="local">'Partially involuting congenital hemangiomas'</a> below.)</p><p></p><p class="headingAnchor" id="H13843101"><span class="h3">Hepatic rapidly involuting congenital hemangiomas</span><span class="headingEndMark"> — </span>RICH can also occur in the liver [<a href="#rid29">29-31</a>]. They present as an abdominal mass in an otherwise healthy infant. Transient thrombocytopenia, hypofibrinogenemia, and anemia are observed in some infants, presumably due to intralesional thrombosis. Arteriovenous shunting may result in heart failure and pulmonary hypertension [<a href="#rid32">32</a>]. Although rare, these lesions can lead to instability in some neonates, with progressive liver failure and death. </p><p>Significant bleeding can occur in some lesions thought to be secondary to the central areas of necrosis. There are reports of infants developing significant ascites needing surgical intervention after the start of regression [<a href="#rid33">33,34</a>]. Ultrasonography demonstrates a well-circumscribed vascular mass with large feeding and draining vessels; coarse subcapsular calcifications can be seen after involution. On magnetic resonance imaging (MRI), the lesions are hyperintense on T2 imaging and hypointense on T1 imaging, with postcontrast imaging demonstrating early peripheral enhancement with eventual diffuse enhancement.</p><p class="headingAnchor" id="H13843108"><span class="h2">Noninvoluting congenital hemangiomas</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features</strong> – NICH are well-circumscribed, round to oval, plaque-like or bossed soft tissue masses; pink to blue-red or purple in color; and most often located on the head and limbs [<a href="#rid3">3</a>]. Overlying telangiectasias and a rim of pallor are characteristic. NICH are typically flatter than RICH. Two morphologic variants have been described: a patch type, characterized by a flat or slightly atrophic surface resembling a vascular stain  (<a class="graphic graphic_picture graphicRef89389" href="/d/graphic/89389.html" rel="external">picture 3</a>), and a nodular/plaque type, associated with prominent tissue swelling  (<a class="graphic graphic_picture graphicRef88908 graphicRef88907" href="/d/graphic/88908.html" rel="external">picture 1B, 1D</a>) [<a href="#rid14">14</a>].</p><p></p><p class="bulletIndent1">The tumor size ranges from a few centimeters to &gt;10 cm. In many cases, peripheral, enlarged draining veins can be seen in the surrounding skin  (<a class="graphic graphic_picture graphicRef89389" href="/d/graphic/89389.html" rel="external">picture 3</a>). Ulceration, scarring, and atrophy are uncommon. On palpation, lesions are typically warm and may have areas of induration with well-circumscribed borders. Nearly one-half of patients in two retrospective case series reported some degree of pain within their lesions [<a href="#rid14">14,35</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical course</strong> – NICH do not resolve spontaneously but tend to enlarge proportionately with the child's growth  (<a class="graphic graphic_picture graphicRef89041" href="/d/graphic/89041.html" rel="external">picture 4</a>). Doppler examination shows persistent fast flow. Although classically thought of as static in size, some do expand over time. In one case series, 9 of 80 NICHs (11 percent) had postnatal growth, after an initial stable period, at ages 2 to 10 years (mean 5.3 years) [<a href="#rid15">15</a>]. Other reports have described expansion of NICH lesions usually during childhood [<a href="#rid16">16-18</a>] but, in rare cases, even during adolescence or early adulthood [<a href="#rid18">18,19</a>]. Surface changes (eg, development of papules or pyogenic granuloma), bleeding, and pain from focal ulceration have also been described [<a href="#rid15">15,16</a>].</p><p></p><p class="headingAnchor" id="H567726"><span class="h2">Partially involuting congenital hemangiomas</span><span class="headingEndMark"> — </span>At birth, PICH are indistinguishable from RICH. They undergo a phase of rapid regression during the first year of life, thus fulfilling the criteria for RICH, but fail to regress completely  (<a class="graphic graphic_picture graphicRef88948" href="/d/graphic/88948.html" rel="external">picture 5</a>). The residual tumor has the clinical, ultrasonographic, and histologic features of NICH [<a href="#rid1">1,36</a>]. In a series of eight patients followed up for 2.5 to 10 years, the hemangiomas decreased in size and thickness in 12 to 30 months and then stabilized [<a href="#rid1">1</a>]. The residual lesions appeared as red-purple patches or plaques with telangiectasias, prominent veins, and a pale rim. Doppler ultrasound imaging revealed low-resistance, high-velocity arterial flow.</p><p class="headingAnchor" id="H567258"><span class="h1">COMPLICATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ulceration and bleeding</strong> – Ulceration with minor bleeding is a frequent complication of large congenital hemangiomas (CHs), particularly during the involution phase. Severe, life-threatening bleeding due to ulceration involving large feeding vessels or trauma is a rare occurrence and may require early surgical excision [<a href="#rid24">24,37-39</a>]. Liver CHs can have life-threatening bleeding.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Thrombocytopenia and coagulopathy</strong> – Transient thrombocytopenia and coagulopathy with hypofibrinogenemia and anemia are potential complications of RICH, especially in liver lesions. The thrombocytopenia is usually mild and typically resolves without treatment in a few weeks [<a href="#rid40">40,41</a>]. In a case series of seven patients with large RICH presenting with thrombocytopenia, low fibrinogen, and high fibrin split products, only one developed petechiae [<a href="#rid40">40</a>]. In all cases, thrombocytopenia and coagulopathy resolved in two weeks.</p><p></p><p class="bulletIndent1">Occasionally, transient thrombocytopenia in combination with coagulopathy and hypofibrinogenemia mimics the Kasabach-Merritt phenomenon, a life-threatening complication of other rare congenital vascular tumors (eg, tufted angioma, kaposiform hemangioendothelioma) characterized by profound and protracted thrombocytopenia and disseminated intravascular coagulation [<a href="#rid40">40,42,43</a>]. (See  <a class="medical medical_review" href="/d/html/86314.html" rel="external">"Tufted angioma, kaposiform hemangioendothelioma (KHE), and Kasabach-Merritt phenomenon (KMP)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Heart failure</strong> – High-output heart failure from arteriovenous shunting and cardiac overload has been reported in a small number of infants with large CH (&gt;7 cm) [<a href="#rid41">41,44</a>]. Heart failure is present at birth or develops in the first days of life. There are rare reports of prenatal diagnosis of heart failure in association with a CH [<a href="#rid41">41</a>]. (See  <a class="medical medical_review" href="/d/html/14373.html" rel="external">"Heart failure in children: Etiology, clinical manifestations, and diagnosis", section on 'Diagnostic evaluation'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pain</strong> – A minority of NICH cause local pain, occasionally to the point where treatment is needed [<a href="#rid14">14,15</a>].</p><p></p><p class="headingAnchor" id="H13843129"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The diagnosis of congenital hemangioma (CH) is based upon history and physical examination in most cases. Imaging studies (eg, ultrasonography and, less commonly, MRI and arteriography) may be helpful to confirm the diagnosis in uncertain cases. A biopsy for histologic examination is necessary if a malignant lesion is suspected. Additional evaluation, including laboratory and cardiac evaluation, may be needed in infants with suspected coagulopathy or congestive heart failure.</p><p class="headingAnchor" id="H790097"><span class="h2">Clinical examination</span><span class="headingEndMark"> — </span>In most cases, the diagnosis of CH is made clinically in a newborn presenting with a fully grown soft tissue mass with overlying telangiectasias and peripheral vasoconstriction  (<a class="graphic graphic_picture graphicRef88800 graphicRef88803 graphicRef88907 graphicRef88908" href="/d/graphic/88800.html" rel="external">picture 1A-D</a>). The presence of the tumor at the time of birth is an important clue to the diagnosis and an important criterion for differentiating CH from infantile hemangiomas, which are usually not clinically evident at the time of delivery [<a href="#rid2">2,45</a>]. The observation of a rapid involution starting a few days after birth is usually sufficient to differentiate RICH from NICH.</p><p class="headingAnchor" id="H790104"><span class="h2">Imaging studies</span><span class="headingEndMark"> — </span>Imaging studies (eg, ultrasonography, MRI, arteriography) may be needed when the diagnosis is unclear. Ultrasonography is useful as first-level imaging modality to differentiate a CH from other soft tissue tumors. If there is any question of the diagnosis, MRI is indicated [<a href="#rid46">46</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>On ultrasonography, both RICH and NICH show a predominantly heterogeneous sonographic structure, diffuse vascularity, high vessel density, and, occasionally, calcifications [<a href="#rid47">47</a>]. Doppler examination reveals a high-flow vascular lesion [<a href="#rid14">14</a>]. In involuting lesions, long, tortuous, and compressible channels with a venous flow signal become a dominant feature [<a href="#rid48">48</a>]. In patients with RICH, the presence on B-mode and Doppler ultrasound of visible vessels, venous ectasia, venous lakes, and arteriovenous shunting suggest increased risk of ulceration, bleeding, and, in the case of arteriovenous shunting, high-output congestive heart failure [<a href="#rid49">49</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>On MRI, RICH and NICH show heterogeneous enhancement, hyperintensity on T2-weighted sequences, flow voids, and absence of peripheral edema. Less-defined borders and more fat stranding help distinguish CH from infantile hemangioma [<a href="#rid47">47</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Angiography reveals heterogeneous parenchyma; large, irregular feeding arteries; venous ectasia; and, in some cases, microshunting [<a href="#rid50">50</a>]. Arterial aneurysms and arteriovenous shunts can also be seen. Angiography is only needed for control of bleeding or to assess anatomic variants if surgical excision is needed.</p><p></p><p class="headingAnchor" id="H63793630"><span class="h2">Prenatal diagnosis</span><span class="headingEndMark"> — </span>Because of their volume and vascularity, RICH are increasingly detected during prenatal ultrasound investigations, usually during the third trimester of pregnancy [<a href="#rid51">51</a>]. Sonographic features include a solid appearance with a homogeneous or slightly heterogeneous pattern isoechoic with the placenta, venous lakes mimicking a cystic component, hemosiderin deposits, and small calcifications [<a href="#rid52">52</a>].</p><p>If RICH is noted on prenatal ultrasound, an antenatal MRI is recommended to better define the characteristics of the tumor. On fetal MRI, the signal of the lesion is slightly hyperintense or hypointense on T2-weighted sequences [<a href="#rid52">52</a>].</p><p class="headingAnchor" id="H790111"><span class="h2">Biopsy and histopathology</span><span class="headingEndMark"> — </span>A biopsy for histopathologic examination is not routinely performed. However, it is warranted if there is a clinical and/or radiologic suspicion of malignant tumor (firmness on palpation, rapid growth, ulceration, and fixation to the fascia).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Routine staining</strong> – RICH, NICH, and PICH show similar histopathologic findings, consisting of small to large lobules of capillary proliferations lined by endothelial cells, with variably shaped lumen (round, slit shaped, or indistinct)  (<a class="graphic graphic_picture graphicRef89836" href="/d/graphic/89836.html" rel="external">picture 6</a>). In some cases, admixed fibrosis or sheets of compact endothelial cells and pericytes can be seen. Many of the endothelial cells show "hobnailed" features. Virtually all have extralobular vessels, which are usually large, tortuous, and irregular [<a href="#rid11">11,14,53</a>]. Focal thromboses and calcifications may be seen. Stromal hemosiderin deposits are common.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Immunohistochemistry</strong> – Immunohistochemical staining for glucose transporter protein-1 (GLUT-1) is negative. This finding helps distinguish CHs from infantile hemangiomas, whose endothelial cells uniformly express GLUT-1 [<a href="#rid12">12</a>]. The lobular components of NICH and RICH stain for Wilms tumor 1 (WT1) protein, a transcription factor activated during angiogenesis, but the larger dysplastic vessels are WT1 negative [<a href="#rid3">3,11,14,28,54,55</a>]. There are no significant correlations between CH subtype and histopathology [<a href="#rid53">53</a>].</p><p></p><p class="headingAnchor" id="H487143464"><span class="h2">Genetic tumor testing</span><span class="headingEndMark"> — </span>Gene testing on frozen or paraffin-embedded tissue for <em>GNAQ</em> or <em>GNA11</em> mutations can help to confirm the diagnosis in uncertain cases [<a href="#rid7">7,8</a>].</p><p class="headingAnchor" id="H641794"><span class="h2">Laboratory testing</span><span class="headingEndMark"> — </span>Laboratory blood tests are not routinely performed in infants with small, uncomplicated CH. However, a complete blood cell count with platelet count and evaluation of the coagulation status (eg, fibrinogen concentration, fibrin split products [D-dimer]) may be warranted in newborns with large tumors at risk of thrombocytopenia and coagulopathy, especially tumors of the liver. (See  <a class="medical medical_review" href="/d/html/97752.html" rel="external">"Neonatal thrombocytopenia: Clinical manifestations, evaluation, and management", section on 'Diagnostic evaluation to identify underlying cause'</a>.)</p><p class="headingAnchor" id="H13843136"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The differential diagnosis of congenital hemangioma (CH) includes other benign vascular tumors, vascular malformations, and benign and malignant nonvascular tumors [<a href="#rid45">45</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Infantile</strong> <strong>hemangioma</strong> – A diagnostic dilemma often arises when the patient's parents/caregivers report that a certain vascular growth "has been there since birth." It is particularly important to ascertain whether a palpable mass (suggesting CH) or just a flat area of discoloration was present at birth, since the latter could represent a premonitory mark of infantile hemangioma  (<a class="graphic graphic_picture graphicRef89391" href="/d/graphic/89391.html" rel="external">picture 7</a>). A history of rapid postnatal growth is typical of infantile hemangioma and usually differentiates infantile hemangioma from CH. When the diagnosis is uncertain, a tissue biopsy for immunohistochemical staining for glucose transporter protein-1 (GLUT-1) can clarify the diagnosis, as infantile hemangioma always stains positive for GLUT-1. (See  <a class="medical medical_review" href="/d/html/5794.html" rel="external">"Infantile hemangiomas: Epidemiology, pathogenesis, clinical features, and complications", section on 'Clinical presentation'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tufted angioma </strong>– Tufted angioma is an uncommon, benign vascular tumor that usually develops in early infancy but may be present at birth. It presents as an infiltrated, firm, dusky, red to violaceous plaque or nodule with typical, overlying hypertrichosis  (<a class="graphic graphic_picture graphicRef89065" href="/d/graphic/89065.html" rel="external">picture 8</a>). Histology shows vascular tufts of tightly packed capillaries randomly dispersed throughout the dermis in a typical "cannonball distribution." Tufted angioma is GLUT-1 negative. (See  <a class="medical medical_review" href="/d/html/86314.html" rel="external">"Tufted angioma, kaposiform hemangioendothelioma (KHE), and Kasabach-Merritt phenomenon (KMP)", section on 'Tufted angioma'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Kaposiform hemangioendothelioma </strong>– Kaposiform hemangioendothelioma is a rare vascular tumor that can be present at birth. Kaposiform hemangioendothelioma appears as a slightly raised, subcutaneous, firm mass with a purpuric, bruised appearance  (<a class="graphic graphic_picture graphicRef89100" href="/d/graphic/89100.html" rel="external">picture 9</a>). It is often associated with the Kasabach-Merritt phenomenon (severe thrombocytopenia and coagulopathy). Histologically, kaposiform hemangioendothelioma is characterized by spindle cells with minimal atypia and infrequent mitoses lining slit-like or crescentic vessels containing hemosiderin. The tumor is GLUT-1 negative. MRI can be helpful in differentiating CHs and kaposiform hemangioendotheliomas, as the latter present as highly infiltrative and heterogeneous masses with uneven and high signal intensity on T2-weighted imaging [<a href="#rid56">56</a>]. (See  <a class="medical medical_review" href="/d/html/86314.html" rel="external">"Tufted angioma, kaposiform hemangioendothelioma (KHE), and Kasabach-Merritt phenomenon (KMP)", section on 'Kaposiform hemangioendothelioma'</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vascular malformations</strong> – Venous malformations are often present at birth as soft, compressible, blue soft tissue masses or plaques  (<a class="graphic graphic_picture graphicRef105862" href="/d/graphic/105862.html" rel="external">picture 10</a>). Doppler ultrasonography demonstrates a slow-flow, ill-defined vascular lesion that is compressible on palpation. Histology shows ectatic, venous-like channels with anomalies in mural cells. Some arteriovenous malformations can present as purple-red, swollen lesions resembling CH  (<a class="graphic graphic_picture graphicRef83576" href="/d/graphic/83576.html" rel="external">picture 11</a>). However, in contrast to CH, venous malformations and combined vascular malformations do not stain for cytoplasmic Wilms tumor 1 (WT1) [<a href="#rid55">55</a>]. (See  <a class="medical medical_review" href="/d/html/110155.html" rel="external">"Venous malformations"</a> and  <a class="medical medical_review" href="/d/html/5789.html" rel="external">"Vascular lesions in the newborn", section on 'Arteriovenous malformations'</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Infantile myofibromatosis/hemangiopericytoma </strong>– Infantile myofibromatosis is a rare fibrous tissue tumor of infancy. In most cases, it presents at birth as solitary or multiple nodules 0.5 cm to several centimeters in diameter that are firm or rubbery in consistency and appear in variable colors (brown, blue, purple, or red)  (<a class="graphic graphic_picture graphicRef89023" href="/d/graphic/89023.html" rel="external">picture 12</a>) [<a href="#rid57">57</a>]. A biopsy is necessary to differentiate infantile myofibromatosis from CH. Histopathology shows a biphasic pattern of peripheral smooth muscle-like fascicles of spindle cells and central areas resembling hemangiopericytoma with rounded pericytes. Given their considerable clinical and histologic overlap, infantile myofibromatosis and infantile hemangiopericytoma are thought to be related entities or identical conditions in different maturation stages [<a href="#rid58">58-60</a>]. (See  <a class="medical medical_review" href="/d/html/5788.html" rel="external">"Skin nodules in newborns and infants", section on 'Infantile myofibromatosis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lipoblastoma and lipoblastomatosis</strong> – Lipoblastoma is a rare, benign infantile tumor that may be present at birth [<a href="#rid61">61</a>]. It presents as a well-circumscribed soft tissue mass located in the subcutaneous tissue on the extremities, trunk, and head and neck area. Histology shows an admixture of mature and immature adipocytes.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Malignant tumors</strong> – Highly vascular malignant tumors (eg, infantile fibrosarcoma, rhabdomyosarcoma, dermatofibrosarcoma protuberans, metastatic neuroblastoma, angiosarcoma) may be present at birth and mimic CH [<a href="#rid57">57</a>]. Clinical signs that raise the suspicion of a malignant lesion and prompt a biopsy for histopathologic examination include firmness on palpation, rapid growth, ulceration, fixation to the fascia, and an atypical appearance on imaging. (See  <a class="medical medical_review" href="/d/html/5788.html" rel="external">"Skin nodules in newborns and infants", section on 'Malignant tumors'</a>.)</p><p></p><p class="headingAnchor" id="H13843143"><span class="h1">MANAGEMENT</span></p><p class="headingAnchor" id="H568061"><span class="h2">Approach</span><span class="headingEndMark"> — </span>The approach to the management of congenital hemangioma (CH) must be individualized based on:</p><p class="bulletIndent1"><span class="glyph">●</span>Tumor size and location</p><p class="bulletIndent1"><span class="glyph">●</span>Tendency for spontaneous involution</p><p class="bulletIndent1"><span class="glyph">●</span>Presence of local or systemic complications</p><p></p><p>For newborns with uncomplicated CH, a wait and watch approach is indicated in the first weeks of life to assess for signs of spontaneous regression  (<a class="graphic graphic_algorithm graphicRef141600" href="/d/graphic/141600.html" rel="external">algorithm 1</a>). Consultation with a specialist or multidisciplinary group with special expertise in vascular anomalies for close monitoring and early treatment is warranted in the following situations:</p><p class="bulletIndent1"><span class="glyph">●</span>Large CH that is at increased risk of complications (eg, ulceration, bleeding, thrombocytopenia, high-output cardiac failure)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>CH associated with function impairment</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Large, complicated liver CH</p><p></p><p>It is important to educate the family/caregivers about the natural history of CH; potential complications; and treatment options for NICH, PICH, or residual skin changes after involution.</p><p class="headingAnchor" id="H2552096319"><span class="h2">Observation and monitoring</span><span class="headingEndMark"> — </span>Observation and monitoring is the preferred approach for most newborns with CH that are noncomplicated and do not impair function. Serial observation in the first few weeks of life allows the clinician to determine whether the tumor shows a tendency to regress and to monitor for occurrence of complications.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>RICH</strong> – It is our practice to examine infants with RICH for at least 12 to 18 months (usually at monthly intervals) to monitor for the occurrence of unexpected complications (eg, ulceration, infection, persistent pain) and whether involution is complete or partial. Evidence from small case series and case reports indicates that most RICH undergo complete regression in 12 to 14 months [<a href="#rid2">2,6,20</a>].</p><p></p><p class="bulletIndent1">We do not recommend routine laboratory monitoring, unless hematologic abnormalities (eg, thrombocytopenia, hypofibrinogenemia, anemia) were previously noted. However, once hematologic abnormalities resolve, laboratory testing is no longer necessary unless there are changes in clinical status that suggest worsening (eg, increased pain, ulceration with bleeding).</p><p></p><p class="bulletIndent1">During the rapid involution phase, the regular application of petrolatum to the lesion surface multiple times per day may be helpful in preventing ulceration [<a href="#rid6">6</a>]. Persistently ulcerated lesions or lesions with a history of repeated bleeding may require early surgical excision. (See <a class="local">'Surgery'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>NICH and PICH</strong> – NICH and PICH do not resolve over time, but treatment may not be necessary if they remain asymptomatic and do not bother the patient [<a href="#rid3">3</a>]. We typically continue to see these patients periodically to evaluate for expansion in size or development of surface changes. The frequency of follow-up visits varies depending upon the age of the patient, with young infants and toddlers being seen every four to six months. For most patients with NICH, annual or biennial visits are sufficient. However, individuals should be re-evaluated if there are new or increased symptoms or concerns about expanding size. Serial photographs taken at each visit are helpful for comparison.</p><p></p><p class="headingAnchor" id="H60604968"><span class="h2">Surgery</span><span class="headingEndMark"> — </span>Early surgical excision with or without preoperative arterial embolization is the treatment of choice in the following situations [<a href="#rid15">15,41,62-65</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Large CH associated with heart failure and/or coagulopathy</p><p class="bulletIndent1"><span class="glyph">●</span>CH complicated by life-threatening bleeding, persistent ulceration, repeated bleeding</p><p class="bulletIndent1"><span class="glyph">●</span>CH that has increased in size and is causing systemic symptoms (pain, ascites, infection)</p><p class="bulletIndent1"><span class="glyph">●</span>Large NICH that impairs function (eg, vision obstruction)</p><p></p><p>Delayed surgical excision and reconstruction is the treatment of choice for:</p><p class="bulletIndent1"><span class="glyph">●</span>NICH or PICH that cause cosmetic concern</p><p class="bulletIndent1"><span class="glyph">●</span>NICH or PICH that show slow volume expansion over time</p><p class="bulletIndent1"><span class="glyph">●</span>Correction of residual skin changes after complete involution of RICH</p><p></p><p>The optimal timing for surgical excision has not been determined. Most experts recommend surgical excision during the preschool age, when the child begins to manifest a facial or body image [<a href="#rid62">62</a>].</p><p>In a series of 53 patients with NICH (age 2 to 30 years), 28 underwent surgical excision [<a href="#rid3">3</a>]. Preoperative arterial embolization was performed in seven patients. No intraoperative or postoperative complications were reported. In another series of 57 patients, 12 patients (1 with RICH, 5 with NICH, and 6 with PICH) underwent surgical excision because of bleeding, esthetic concerns, or pain [<a href="#rid35">35</a>].</p><p class="headingAnchor" id="H4003528735"><span class="h2">Endovascular embolization</span><span class="headingEndMark"> — </span>Data on the use of percutaneous endovascular embolization for the treatment of problematic CH are limited. In most cases, embolization has been used preoperatively to control bleeding or reduce the tumor mass before surgery [<a href="#rid64">64-67</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>In one report, arterial embolization was successfully used to treat a newborn with a large CH associated with coagulopathy [<a href="#rid63">63</a>]. The tumor subsequently underwent spontaneous regression, fulfilling the diagnosis of RICH.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Embolization with N-butyl-2-cyanoacrylate (NBCA) and/or percutaneous sclerotherapy has been described in a series of 10 patients with NICH [<a href="#rid67">67</a>]. There are a few reports of percutaneous cryoablation for the management of symptomatic NICH [<a href="#rid68">68</a>]. Indications for treatment included cosmetic deformity, location not amenable to primary surgical resection, and need to reduce the tumor volume before resection. Direct percutaneous sclerotherapy with 98% ethanol was used alone or in combination with endovascular embolization. Two patients underwent subsequent surgical resection.</p><p></p><p class="headingAnchor" id="H3462516354"><span class="h2">Laser therapy</span><span class="headingEndMark"> — </span>Pulsed dye laser treatment may be helpful in reducing the appearance of superficial telangiectasias [<a href="#rid62">62</a>]. (See  <a class="medical medical_review" href="/d/html/13638.html" rel="external">"Laser and light therapy for cutaneous vascular lesions", section on 'Involuting and resolved lesions'</a>.)</p><p class="headingAnchor" id="H567850"><span class="h2">Treatment of complications</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ulceration</strong> – Superficial ulcerations can be treated conservatively with meticulous wound care, which involves the use of topical antibiotics (eg, <a class="drug drug_general" data-topicid="9668" href="/d/drug information/9668.html" rel="external">mupirocin</a> 2% cream), barrier creams (eg, petrolatum), and nonadherent dressings [<a href="#rid69">69</a>]. Crusting should be debrided with diluted <a class="drug drug_general" data-topicid="113931" href="/d/drug information/113931.html" rel="external">hydrogen peroxide</a> or <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a> soaks two to three times daily since crusting prevents re-epithelization and favors infection. Pulsed dye laser treatment may be a treatment option for ulcerations that do not respond to topical therapy.</p><p></p><p class="bulletIndent1">Pain associated with ulceration may be severe. Appropriate analgesia with oral <a class="drug drug_general" data-topicid="9242" href="/d/drug information/9242.html" rel="external">acetaminophen</a> or a topical anesthetic agent (ie, <a class="drug drug_general" data-topicid="9558" href="/d/drug information/9558.html" rel="external">lidocaine</a> hydrochloride 2% ointment) may be warranted. (See  <a class="medical medical_review" href="/d/html/5018.html" rel="external">"Management and prevention of pain in neonates"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bleeding</strong> – Minor bleeding can be controlled with compression. Persistent or major bleeding from ulceration or trauma may require arterial embolization and/or surgical excision of the tumor [<a href="#rid24">24,38,39</a>]. In two reported cases, control of minor bleeding from superficial ulcerations was successfully achieved with topical <a class="drug drug_general" data-topicid="10011" href="/d/drug information/10011.html" rel="external">tranexamic acid</a> and compression [<a href="#rid37">37</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Thrombocytopenia and coagulopathy</strong> – The thrombocytopenia associated with CH is transient and usually resolves in a few weeks without treatment. Systemic corticosteroids have been used in a small number of infants with RICH and thrombocytopenia, but their role in the normalization of the platelet count remains uncertain [<a href="#rid40">40</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Heart failure</strong> – For infants who develop CH-induced heart failure, embolization and/or surgical excision of the tumor in addition to medical treatment is required in most cases [<a href="#rid41">41</a>]. The medical management of congestive heart failure in infants and children is discussed separately. (See  <a class="medical medical_review" href="/d/html/14520.html" rel="external">"Heart failure in children: Management"</a>.)</p><p></p><p class="headingAnchor" id="H1633204"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>Infants with uncomplicated RICH have a favorable prognosis. The prognosis is guarded for infants with severe bleeding and infants who develop heart failure. In a review of 17 patients with large congenital hemangioma (CH) and heart failure, four died in the first weeks of life despite embolization or excision of the tumor and medical treatment of heart failure [<a href="#rid41">41</a>].</p><p>The prognosis of NICH is generally favorable. Lesions that are not excised most often grow in proportion with the child and persist unchanged throughout adulthood [<a href="#rid3">3</a>]. However, a subset expand over time, albeit slowly, and recurrent discomfort or pain can occur in some cases [<a href="#rid18">18</a>].</p><p class="headingAnchor" id="H13843150"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical subtypes and pathogenesis</strong> – Congenital hemangiomas (CHs) are rare, benign vascular tumors that are present and fully grown at birth. Based upon their natural history, three major subtypes have been recognized: rapidly involuting congenital hemangioma (RICH), noninvoluting congenital hemangioma (NICH), and an intermediate subtype called partially involuting congenital hemangioma (PICH). There is increasing evidence that all types of CH are due to somatic activating mutations in <em>GNAQ</em> and <em>GNA11</em>. (See <a class="local">'Clinical subtypes'</a> above and <a class="local">'Pathogenesis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical presentation</strong>:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>RICH</strong> – RICH usually present as solitary, violaceous soft tissue masses with coarse telangiectasias and prominent peripheral veins, most often located on the head, neck, or lower extremities  (<a class="graphic graphic_picture graphicRef88800 graphicRef88803" href="/d/graphic/88800.html" rel="external">picture 1A, 1C</a>). Involution typically starts a few days to weeks after birth and, in most cases, is complete in 6 to 14 months  (<a class="graphic graphic_picture graphicRef88807" href="/d/graphic/88807.html" rel="external">picture 2</a>).<strong> </strong>(See <a class="local">'Rapidly involuting congenital hemangiomas'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>PICH</strong> – At birth, PICH are indistinguishable from RICH. They undergo a phase of rapid regression and then stabilize  (<a class="graphic graphic_picture graphicRef88948" href="/d/graphic/88948.html" rel="external">picture 5</a>). The residual lesion is identical to NICH. (See <a class="local">'Rapidly involuting congenital hemangiomas'</a> above and <a class="local">'Partially involuting congenital hemangiomas'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>NICH</strong> – NICH present as well-circumscribed, plaque-like or bossed soft tissue masses with overlying telangiectasias and a characteristic rim of pallor  (<a class="graphic graphic_picture graphicRef88907 graphicRef88908" href="/d/graphic/88907.html" rel="external">picture 1B, 1D</a>). NICH do not resolve spontaneously but tend to grow proportionately with the child's somatic growth. In a minority of cases, NICH can slowly expand over time. (See <a class="local">'Noninvoluting congenital hemangiomas'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – The diagnosis of CH is made clinically in a newborn presenting with a fully grown soft tissue mass with overlying telangiectasias and peripheral vasoconstriction  (<a class="graphic graphic_picture graphicRef88800 graphicRef88803 graphicRef88907 graphicRef88908" href="/d/graphic/88800.html" rel="external">picture 1A-D</a>). The rapid involution starting in the first few weeks after birth differentiates RICH from NICH. Imaging studies (eg, ultrasonography, MRI, arteriography) and/or a biopsy for histopathologic examination may be warranted if the diagnosis is unclear or a malignant tumor is suspected. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management </strong>– The approach to the management of CH must be individualized based on tumor size and location, tendency for spontaneous involution, and presence of local or systemic complications  (<a class="graphic graphic_algorithm graphicRef141600" href="/d/graphic/141600.html" rel="external">algorithm 1</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Observation and monitoring </strong>– For most newborns with uncomplicated CH, we suggest serial observation rather than surgery (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>) in order to determine whether the tumor shows a tendency to regress and monitor for occurrence of complications. (See <a class="local">'Observation and monitoring'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>RICH</strong> – We typically examine infants with RICH at monthly intervals until complete involution. All RICH undergo complete regression, typically within 12 to 14 months. Of note, RICH involving the liver require serial evaluations until a marked decrease in size (or disappearance) has been documented with imaging. If there is an increase in size or change in symptomatology, possible causes (eg, intratumoral bleeding) should be investigated.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>NICH/PICH </strong>– Observation is a reasonable approach for NICH and PICH if they remain asymptomatic and do not bother the patient. We typically see these patients every four to six months until stabilization and for one to two years thereafter. Serial evaluations every year or two are often sufficient in teens and adults unless symptoms, complications (eg, pain, infection), or progression develop. Serial photographs are helpful for comparison.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Surgery</strong> <strong>and endovascular embolization </strong>– For large CH complicated by life-threatening or repeated bleeding, heart failure and/or coagulopathy, persistent ulceration, or function impairment, we suggest early surgical excision with or without preoperative endovascular embolization rather than embolization alone or other interventions (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Preoperative endovascular embolization may be used on a case-by-case basis to reduce tumor volume and control bleeding before resection. For patients with a CH in a location not amenable to primary surgical resection, endovascular embolization is an acceptable option.</p><p></p><p class="bulletIndent2">For NICH and PICH that cause cosmetic concern or expand over time and for correction of residual skin changes after RICH involution, we suggest delayed (rather than immediate) surgical excision (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Most experts recommend surgical excision during the preschool age, when the child begins to manifest a facial or body image. (See <a class="local">'Surgery'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prognosis </strong>–<strong> </strong>Infants with uncomplicated RICH and NICH have a favorable prognosis. The prognosis is guarded for infants with severe bleeding and for infants who develop heart failure. (See <a class="local">'Prognosis'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Nasseri E, Piram M, McCuaig CC, et al. Partially involuting congenital hemangiomas: a report of 8 cases and review of the literature. J Am Acad Dermatol 2014; 70:75.</a></li><li><a class="nounderline abstract_t">Boon LM, Enjolras O, Mulliken JB. Congenital hemangioma: evidence of accelerated involution. J Pediatr 1996; 128:329.</a></li><li><a class="nounderline abstract_t">Enjolras O, Mulliken JB, Boon LM, et al. Noninvoluting congenital hemangioma: a rare cutaneous vascular anomaly. Plast Reconstr Surg 2001; 107:1647.</a></li><li><a class="nounderline abstract_t">Kanada KN, Merin MR, Munden A, Friedlander SF. A prospective study of cutaneous findings in newborns in the United States: correlation with race, ethnicity, and gestational status using updated classification and nomenclature. J Pediatr 2012; 161:240.</a></li><li><a class="nounderline abstract_t">Yang B, Li L, Zhang LX, et al. Clinical Characteristics and Treatment Options of Infantile Vascular Anomalies. Medicine (Baltimore) 2015; 94:e1717.</a></li><li><a class="nounderline abstract_t">Krol A, MacArthur CJ. Congenital hemangiomas: rapidly involuting and noninvoluting congenital hemangiomas. Arch Facial Plast Surg 2005; 7:307.</a></li><li><a class="nounderline abstract_t">Ayturk UM, Couto JA, Hann S, et al. Somatic Activating Mutations in GNAQ and GNA11 Are Associated with Congenital Hemangioma. Am J Hum Genet 2016; 98:789.</a></li><li><a class="nounderline abstract_t">Funk T, Lim Y, Kulungowski AM, et al. Symptomatic Congenital Hemangioma and Congenital Hemangiomatosis Associated With a Somatic Activating Mutation in GNA11. JAMA Dermatol 2016; 152:1015.</a></li><li><a class="nounderline abstract_t">Lim YH, Bacchiocchi A, Qiu J, et al. GNA14 Somatic Mutation Causes Congenital and Sporadic Vascular Tumors by MAPK Activation. Am J Hum Genet 2016; 99:443.</a></li><li><a class="nounderline abstract_t">Bean GR, Joseph NM, Gill RM, et al. Recurrent GNAQ mutations in anastomosing hemangiomas. Mod Pathol 2017; 30:722.</a></li><li><a class="nounderline abstract_t">North PE, Waner M, James CA, et al. Congenital nonprogressive hemangioma: a distinct clinicopathologic entity unlike infantile hemangioma. Arch Dermatol 2001; 137:1607.</a></li><li><a class="nounderline abstract_t">North PE, Waner M, Mizeracki A, Mihm MC Jr. GLUT1: a newly discovered immunohistochemical marker for juvenile hemangiomas. Hum Pathol 2000; 31:11.</a></li><li><a class="nounderline abstract_t">Picard A, Boscolo E, Khan ZA, et al. IGF-2 and FLT-1/VEGF-R1 mRNA levels reveal distinctions and similarities between congenital and common infantile hemangioma. Pediatr Res 2008; 63:263.</a></li><li><a class="nounderline abstract_t">Lee PW, Frieden IJ, Streicher JL, et al. Characteristics of noninvoluting congenital hemangioma: a retrospective review. J Am Acad Dermatol 2014; 70:899.</a></li><li><a class="nounderline abstract_t">Cossio ML, Dubois J, McCuaig CC, et al. Non-involuting congenital hemangiomas (NICH) with postnatal atypical growth: A case series. Pediatr Dermatol 2019; 36:466.</a></li><li><a class="nounderline abstract_t">Hua C, Wang L, Jin Y, et al. A case series of tardive expansion congenital hemangioma: A variation of noninvoluting congenital hemangioma or a new hemangiomatous entity? J Am Acad Dermatol 2021; 84:1371.</a></li><li><a class="nounderline abstract_t">Knöpfel N, Wälchli R, Luchsinger I, et al. Congenital hemangioma exhibiting postnatal growth. Pediatr Dermatol 2019; 36:548.</a></li><li><a class="nounderline abstract_t">West ES, Totoraitis K, Yadav B, et al. Atypical presentations of congenital hemangiomas: Extending the clinical phenotype. Pediatr Dermatol 2019; 36:835.</a></li><li><a class="nounderline abstract_t">Konanur A, Jimenez JE, Kochin M, et al. Non-involuting congenital hemangioma with delayed hypertrophy: A case series. Int J Pediatr Otorhinolaryngol 2022; 157:111102.</a></li><li><a class="nounderline abstract_t">Browning JC, Metry DW. Rapidly involuting congenital hemangioma: case report and review of the literature. Dermatol Online J 2008; 14:11.</a></li><li><a class="nounderline abstract_t">Roncero M, Martinez de Salinas A, Izquierdo N, Unamuno P. Rapidly involuting congenital haemangioma. Clin Exp Dermatol 2009; 34:937.</a></li><li><a class="nounderline abstract_t">Mulliken JB, Bischoff J, Kozakewich HP. Multifocal rapidly involuting congenital hemangioma: a link to chorangioma. Am J Med Genet A 2007; 143A:3038.</a></li><li><a class="nounderline abstract_t">Blumenthal S, Stefanko N, Cossio ML, et al. Multifocal congenital hemangioma: Expanding the pathogenesis of "neonatal hemangiomatosis". Pediatr Dermatol 2019; 36:720.</a></li><li><a class="nounderline abstract_t">Vildy S, Macher J, Abasq-Thomas C, et al. Life-threatening hemorrhaging in neonatal ulcerated congenital hemangioma: two case reports. JAMA Dermatol 2015; 151:422.</a></li><li><a class="nounderline abstract_t">Hughes R, McAleer M, Watson R, et al. Rapidly involuting congenital hemangioma with pustules: two cases. Pediatr Dermatol 2014; 31:398.</a></li><li><a class="nounderline abstract_t">Ozcan UA. Rapidly involuting congenital hemangioma: a case of complete prenatal involution. J Clin Ultrasound 2010; 38:85.</a></li><li><a class="nounderline abstract_t">Lopez-Gutierrez JC, Diaz M, Ros Z. Giant rapidly involuting congenital hemangioma of the face: 15-year follow-up. Arch Facial Plast Surg 2005; 7:316.</a></li><li><a class="nounderline abstract_t">Berenguer B, Mulliken JB, Enjolras O, et al. Rapidly involuting congenital hemangioma: clinical and histopathologic features. Pediatr Dev Pathol 2003; 6:495.</a></li><li><a class="nounderline abstract_t">Iacobas I, Phung TL, Adams DM, et al. Guidance Document for Hepatic Hemangioma (Infantile and Congenital) Evaluation and Monitoring. J Pediatr 2018; 203:294.</a></li><li><a class="nounderline abstract_t">Kulungowski AM, Alomari AI, Chawla A, et al. Lessons from a liver hemangioma registry: subtype classification. J Pediatr Surg 2012; 47:165.</a></li><li><a class="nounderline abstract_t">Roebuck D, Sebire N, Lehmann E, Barnacle A. Rapidly involuting congenital haemangioma (RICH) of the liver. Pediatr Radiol 2012; 42:308.</a></li><li><a class="nounderline abstract_t">Zenzen W, Perez-Atayde AR, Elisofon SA, et al. Hepatic failure in a rapidly involuting congenital hemangioma of the liver: failure of embolotherapy. Pediatr Radiol 2009; 39:1118.</a></li><li><a class="nounderline abstract_t">Klein M, Chang AK, Vasudevan SA, et al. Clinically significant ascites as an indication for resection of rapidly involuting congenital hepatic hemangiomas. Pediatr Blood Cancer 2018; 65:e27222.</a></li><li><a class="nounderline abstract_t">Hoornaert E, Clapuyt P, Dumitriu D, et al. Conservative management of congenital hepatic hemangioma complicated by ascites. Clin Case Rep 2022; 10:e05938.</a></li><li><a class="nounderline abstract_t">Braun V, Prey S, Gurioli C, et al. Congenital haemangiomas: a single-centre retrospective review. BMJ Paediatr Open 2020; 4:e000816.</a></li><li><a class="nounderline abstract_t">Mulliken JB, Enjolras O. Congenital hemangiomas and infantile hemangioma: missing links. J Am Acad Dermatol 2004; 50:875.</a></li><li><a class="nounderline abstract_t">Powell J, Blouin MM, David M, Dubois J. Bleeding in congenital hemangiomas: crusting as a clinical predictive sign and usefulness of tranexamic acid. Pediatr Dermatol 2012; 29:182.</a></li><li><a class="nounderline abstract_t">Agesta N, Boralevi F, Sarlangue J, et al. Life-threatening haemorrhage as a complication of a congenital haemangioma. Acta Paediatr 2003; 92:1216.</a></li><li><a class="nounderline abstract_t">Nolan M, Hartin CW Jr, Pierre J, Ozgediz DE. Life-threatening hemorrhage from a congenital hemangioma caused by birth trauma. J Pediatr Surg 2012; 47:1016.</a></li><li><a class="nounderline abstract_t">Baselga E, Cordisco MR, Garzon M, et al. Rapidly involuting congenital haemangioma associated with transient thrombocytopenia and coagulopathy: a case series. Br J Dermatol 2008; 158:1363.</a></li><li><a class="nounderline abstract_t">Weitz NA, Lauren CT, Starc TJ, et al. Congenital cutaneous hemangioma causing cardiac failure: a case report and review of the literature. Pediatr Dermatol 2013; 30:e180.</a></li><li><a class="nounderline abstract_t">Andreu-Barasoain M, Naz E, Díaz M, López-Estebaranz JL. Rapidly involuting congenital hemangioma associated with transient anemia and thrombocytopenia. Int J Dermatol 2013; 52:1025.</a></li><li><a class="nounderline abstract_t">Rangwala S, Wysong A, Tollefson MM, et al. Rapidly involuting congenital hemangioma associated with profound, transient thrombocytopenia. Pediatr Dermatol 2014; 31:402.</a></li><li><a class="nounderline abstract_t">Hsiao CH, Tsao PN, Hsieh WS, Chou HC. Huge, alarming congenital hemangioma of the scalp presenting as heart failure and Kasabach-Merritt syndrome: a case report. Eur J Pediatr 2007; 166:619.</a></li><li><a class="nounderline abstract_t">Frieden IJ, Rogers M, Garzon MC. Conditions masquerading as infantile haemangioma: Part 1. Australas J Dermatol 2009; 50:77.</a></li><li><a class="nounderline abstract_t">Esposito F, D'Auria D, Ferrara D, et al. Hepatic hemangiomas in childhood: the spectrum of radiologic findings. A pictorial essay. J Ultrasound 2023; 26:261.</a></li><li><a class="nounderline abstract_t">Gorincour G, Kokta V, Rypens F, et al. Imaging characteristics of two subtypes of congenital hemangiomas: rapidly involuting congenital hemangiomas and non-involuting congenital hemangiomas. Pediatr Radiol 2005; 35:1178.</a></li><li><a class="nounderline abstract_t">Rogers M, Lam A, Fischer G. Sonographic findings in a series of rapidly involuting congenital hemangiomas (RICH). Pediatr Dermatol 2002; 19:5.</a></li><li><a class="nounderline abstract_t">Waelti SL, Rypens F, Damphousse A, et al. Ultrasound findings in rapidly involuting congenital hemangioma (RICH) - beware of venous ectasia and venous lakes. Pediatr Radiol 2018; 48:586.</a></li><li><a class="nounderline abstract_t">Konez O, Burrows PE, Mulliken JB, et al. Angiographic features of rapidly involuting congenital hemangioma (RICH). Pediatr Radiol 2003; 33:15.</a></li><li><a class="nounderline abstract_t">Liao M, He B, Xiao Z, et al. Prenatal ultrasound evaluation of fetal cutaneous hemangioma and related complications. J Matern Fetal Neonatal Med 2023; 36:2157257.</a></li><li><a class="nounderline abstract_t">Elia D, Garel C, Enjolras O, et al. Prenatal imaging findings in rapidly involuting congenital hemangioma of the skull. Ultrasound Obstet Gynecol 2008; 31:572.</a></li><li><a class="nounderline abstract_t">El Zein S, Boccara O, Soupre V, et al. The histopathology of congenital haemangioma and its clinical correlations: a long-term follow-up study of 55 cases. Histopathology 2020; 77:275.</a></li><li><a class="nounderline abstract_t">Trindade F, Tellechea O, Torrelo A, et al. Wilms tumor 1 expression in vascular neoplasms and vascular malformations. Am J Dermatopathol 2011; 33:569.</a></li><li><a class="nounderline abstract_t">Al Dhaybi R, Powell J, McCuaig C, Kokta V. Differentiation of vascular tumors from vascular malformations by expression of Wilms tumor 1 gene: evaluation of 126 cases. J Am Acad Dermatol 2010; 63:1052.</a></li><li><a class="nounderline abstract_t">Hu Y, Song D, Wu C, et al. Clinical and imaging features of Kaposiform hemangioendothelioma in infants. Heliyon 2023; 9:e15425.</a></li><li><a class="nounderline abstract_t">Frieden IJ, Rogers M, Garzon MC. Conditions masquerading as infantile haemangioma: Part 2. Australas J Dermatol 2009; 50:153.</a></li><li><a class="nounderline abstract_t">Gengler C, Guillou L. Solitary fibrous tumour and haemangiopericytoma: evolution of a concept. Histopathology 2006; 48:63.</a></li><li><a class="nounderline abstract_t">Variend S, Bax NM, van Gorp J. Are infantile myofibromatosis, congenital fibrosarcoma and congenital haemangiopericytoma histogenetically related? Histopathology 1995; 26:57.</a></li><li><a class="nounderline abstract_t">Mentzel T, Calonje E, Nascimento AG, Fletcher CD. Infantile hemangiopericytoma versus infantile myofibromatosis. Study of a series suggesting a continuous spectrum of infantile myofibroblastic lesions. Am J Surg Pathol 1994; 18:922.</a></li><li><a class="nounderline abstract_t">Pham NS, Poirier B, Fuller SC, et al. Pediatric lipoblastoma in the head and neck: a systematic review of 48 reported cases. Int J Pediatr Otorhinolaryngol 2010; 74:723.</a></li><li><a class="nounderline abstract_t">Astner S, Anderson RR. Treating vascular lesions. Dermatol Ther 2005; 18:267.</a></li><li><a class="nounderline abstract_t">Peng YH, Lin MC, Liu WL, Jan SL. Case report: Transcatheter arterial embolization in a newborn with cervical rapidly involuting congenital hemangioma and Kasabach-Merritt phenomenon. Front Pediatr 2023; 11:1073090.</a></li><li><a class="nounderline abstract_t">AlShaker S, Jivraj I, Chen H, et al. Management of a Large Congenital Hemangioma Obstructing Visual Axis: A Case Report and Review of Literature. Ophthalmic Plast Reconstr Surg 2019; 35:e154.</a></li><li><a class="nounderline abstract_t">Alluhaybi AA, Abdulqader SB, Altuhayni K, et al. Preoperative trans-arterial embolization of a giant scalp congenital hemangioma associated with cardiac failure in a premature newborn. J Int Med Res 2020; 48:300060520977589.</a></li><li><a class="nounderline abstract_t">Ooi KG, Wenderoth JD, Francis IC, Wilcsek GA. Selective embolization and resection of a large noninvoluting congenital hemangioma of the lower eyelid. Ophthalmic Plast Reconstr Surg 2009; 25:111.</a></li><li><a class="nounderline abstract_t">Patel A, De Leacy R, Berenstein A. Angiographic and Clinical Features of Noninvoluting Congenital Hemangiomas. AJNR Am J Neuroradiol 2019; 40:845.</a></li><li><a class="nounderline abstract_t">Khalil A, Garg T, Weiss CR. Percutaneous Cryoablation for Symptomatic Peripheral Congenital Hemangioma. J Vasc Interv Radiol 2022; 33:1349.</a></li><li><a class="nounderline abstract_t">Maguiness SM, Frieden IJ. Management of difficult infantile haemangiomas. Arch Dis Child 2012; 97:266.</a></li></ol></div><div id="topicVersionRevision">Topic 13727 Version 11.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24176519" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Partially involuting congenital hemangiomas: a report of 8 cases and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8774499" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Congenital hemangioma: evidence of accelerated involution.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11391180" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Noninvoluting congenital hemangioma: a rare cutaneous vascular anomaly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22497908" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : A prospective study of cutaneous findings in newborns in the United States: correlation with race, ethnicity, and gestational status using updated classification and nomenclature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26448027" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Clinical Characteristics and Treatment Options of Infantile Vascular Anomalies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16172338" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Congenital hemangiomas: rapidly involuting and noninvoluting congenital hemangiomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27058448" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Somatic Activating Mutations in GNAQ and GNA11 Are Associated with Congenital Hemangioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27438697" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Symptomatic Congenital Hemangioma and Congenital Hemangiomatosis Associated With a Somatic Activating Mutation in GNA11.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27476652" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : GNA14 Somatic Mutation Causes Congenital and Sporadic Vascular Tumors by MAPK Activation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28084343" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Recurrent GNAQ mutations in anastomosing hemangiomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11735711" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Congenital nonprogressive hemangioma: a distinct clinicopathologic entity unlike infantile hemangioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10665907" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : GLUT1: a newly discovered immunohistochemical marker for juvenile hemangiomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18287964" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : IGF-2 and FLT-1/VEGF-R1 mRNA levels reveal distinctions and similarities between congenital and common infantile hemangioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24630000" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Characteristics of noninvoluting congenital hemangioma: a retrospective review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31033005" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Non-involuting congenital hemangiomas (NICH) with postnatal atypical growth: A case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32032694" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : A case series of tardive expansion congenital hemangioma: A variation of noninvoluting congenital hemangioma or a new hemangiomatous entity?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30900306" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Congenital hemangioma exhibiting postnatal growth.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31576603" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Atypical presentations of congenital hemangiomas: Extending the clinical phenotype.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35489230" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Non-involuting congenital hemangioma with delayed hypertrophy: A case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18627733" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Rapidly involuting congenital hemangioma: case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20055889" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Rapidly involuting congenital haemangioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17937433" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Multifocal rapidly involuting congenital hemangioma: a link to chorangioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31231857" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Multifocal congenital hemangioma: Expanding the pathogenesis of "neonatal hemangiomatosis".</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25565634" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Life-threatening hemorrhaging in neonatal ulcerated congenital hemangioma: two case reports.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24689686" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Rapidly involuting congenital hemangioma with pustules: two cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19899150" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Rapidly involuting congenital hemangioma: a case of complete prenatal involution.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16172340" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Giant rapidly involuting congenital hemangioma of the face: 15-year follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15018449" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Rapidly involuting congenital hemangioma: clinical and histopathologic features.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30244993" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Guidance Document for Hepatic Hemangioma (Infantile and Congenital) Evaluation and Monitoring.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22244411" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Lessons from a liver hemangioma registry: subtype classification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22302317" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Rapidly involuting congenital haemangioma (RICH) of the liver.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19588131" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Hepatic failure in a rapidly involuting congenital hemangioma of the liver: failure of embolotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29741223" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Clinically significant ascites as an indication for resection of rapidly involuting congenital hepatic hemangiomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35846904" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Conservative management of congenital hepatic hemangioma complicated by ascites.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33324762" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Congenital haemangiomas: a single-centre retrospective review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15153887" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Congenital hemangiomas and infantile hemangioma: missing links.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21995591" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Bleeding in congenital hemangiomas: crusting as a clinical predictive sign and usefulness of tranexamic acid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14632343" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Life-threatening haemorrhage as a complication of a congenital haemangioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22595593" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Life-threatening hemorrhage from a congenital hemangioma caused by birth trauma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18410425" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Rapidly involuting congenital haemangioma associated with transient thrombocytopenia and coagulopathy: a case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23025620" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Congenital cutaneous hemangioma causing cardiac failure: a case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23489172" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Rapidly involuting congenital hemangioma associated with transient anemia and thrombocytopenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22937785" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Rapidly involuting congenital hemangioma associated with profound, transient thrombocytopenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16937128" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Huge, alarming congenital hemangioma of the scalp presenting as heart failure and Kasabach-Merritt syndrome: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19397559" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Conditions masquerading as infantile haemangioma: Part 1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36071345" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Hepatic hemangiomas in childhood: the spectrum of radiologic findings. A pictorial essay.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16078073" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Imaging characteristics of two subtypes of congenital hemangiomas: rapidly involuting congenital hemangiomas and non-involuting congenital hemangiomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11860561" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Sonographic findings in a series of rapidly involuting congenital hemangiomas (RICH).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29362838" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Ultrasound findings in rapidly involuting congenital hemangioma (RICH) - beware of venous ectasia and venous lakes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12497230" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Angiographic features of rapidly involuting congenital hemangioma (RICH).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36521849" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Prenatal ultrasound evaluation of fetal cutaneous hemangioma and related complications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18432598" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Prenatal imaging findings in rapidly involuting congenital hemangioma of the skull.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32281140" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : The histopathology of congenital haemangioma and its clinical correlations: a long-term follow-up study of 55 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21697701" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Wilms tumor 1 expression in vascular neoplasms and vascular malformations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21093662" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Differentiation of vascular tumors from vascular malformations by expression of Wilms tumor 1 gene: evaluation of 126 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37159688" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Clinical and imaging features of Kaposiform hemangioendothelioma in infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19659975" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Conditions masquerading as infantile haemangioma: Part 2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16359538" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Solitary fibrous tumour and haemangiopericytoma: evolution of a concept.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7713484" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Are infantile myofibromatosis, congenital fibrosarcoma and congenital haemangiopericytoma histogenetically related?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8067513" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Infantile hemangiopericytoma versus infantile myofibromatosis. Study of a series suggesting a continuous spectrum of infantile myofibroblastic lesions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20472310" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Pediatric lipoblastoma in the head and neck: a systematic review of 48 reported cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16229727" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Treating vascular lesions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36911036" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Case report: Transcatheter arterial embolization in a newborn with cervical rapidly involuting congenital hemangioma and Kasabach-Merritt phenomenon.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31593044" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Management of a Large Congenital Hemangioma Obstructing Visual Axis: A Case Report and Review of Literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33296609" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Preoperative trans-arterial embolization of a giant scalp congenital hemangioma associated with cardiac failure in a premature newborn.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19300152" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Selective embolization and resection of a large noninvoluting congenital hemangioma of the lower eyelid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31023659" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Angiographic and Clinical Features of Noninvoluting Congenital Hemangiomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35850453" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Percutaneous Cryoablation for Symptomatic Peripheral Congenital Hemangioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22215816" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Management of difficult infantile haemangiomas.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
